Understanding the mechanisms that underlie BP (blood pressure) variation in humans and animal models may provide important clues for reducing the burden of uncontrolled hypertension in industrialized societies. High BP is often associated with increased signalling via G-protein-coupled receptors. Three members of the RGS (regulator of G-protein signalling) superfamily RGS2, RGS4 and RGS5 have been implicated in the attenuation of G-protein signalling pathways in vascular and cardiac myocytes, as well as cells of the kidney and autonomic nervous system. In the present review, we discuss the current state of knowledge regarding their differential expression and function in cardiovascular tissues, and the likelihood that one or more of these alleles are candidate hypertension genes. Together, findings from the studies described herein suggest that development of methods to modulate the expression and function of RGS proteins may be a possible strategy for the treatment and prevention of hypertension and cardiovascular disease.
INTRODUCTION
Hypertension is a prevalent condition within the general population of industrialized countries that increases the risk of stroke, heart disease and renal dysfunction and is thus an important target of clinical research. The aetiological basis of high BP (blood pressure) remains poorly understood [1] . Research efforts to uncover the mechanisms underlying its onset are complicated by the fact that hypertension typically arises as a complex quantitative trait that is affected by varying combinations of genetic and environmental factors. Several QTLs (quantitative trait loci) associated with hypertension have been identified in animal models [2, 3] and the human population [4] ; however, the candidate gene(s) within these regions have remained elusive [5] , due to the large size of the genomic regions identified and the potential contribution of complicating factors, such as epigenetic heterogeneity and copy number variation. One QTL region that is common to both hypertensive animal and human populations is found on the q arm of chromosome 1 [3, 4] . Clustered within the genomic region containing this QTL are genes encoding a large number of heterotrimeric G-protein signalling inhibitors, including RGS2, RGS4 and RGS5 (where RGS is regulator of G-protein signalling). Results from our laboratory and others show that these three genes are very highly expressed in aortic VSMCs (vascular smooth muscle cells), as well as other
Figure 1 Summary of RGS protein expression and function in the cardiovascular system
Within the heart, kidneys, brain and microcirculation, the RGS protein(s) expressed are marked (RGS2, blue; RGS4, green; RGS5, purple) with the receptor signalling pathways and physiological processes that they are known to regulate shown in red. Abbreviations: AT1R, AT 1 receptor; CCD, cortical collecting ducts; ETR, endothelin receptor; M2R, muscarinic M 2 receptor; P2YR, P2Y purinergic receptor; SA, sinoatrial; S1PR, S1P receptor; VASP, vasodilator-stimulated phosphoprotein; VR, vasopressin receptor.
tissues important for BP homoeostasis, including the heart and kidneys (Figure 1 ). On the basis on their potent activity as key regulators of GPCR (G-protein-coupled receptor) function, we suggest that they may be candidate alleles for BP variation. Herein, we summarize the current state of knowledge regarding the role of RGS2, RGS4 and RGS5 as mediators of BP regulation and cardiovascular function.
HETEROTRIMERIC G-PROTEINS MEDIATE CARDIOVASCULAR SIGNALLING EVENTS
Heterotrimeric G-proteins act as intracellular relays for environmental stimuli [6] . Specifically, GPCRs mediate the activity of several important cardiovascular hormones and neurotransmitters, including noradrenaline (norepinephrine), adrenaline (epinephrine), AngII (angiotensin II), endothelin, thrombin, vasopressin, acetylcholine, seratonin and S1P (sphingosine-1-phosphate). G-proteins are also widely expressed throughout the cardiovascular system and thus play an important role in both the development and physiological regulation of the cardiovascular system. Hypertension is often associated with the increased activity of GPCR-mediated signalling in the heart and blood vessels. Accordingly, these pathways are common targets of drugs and inhibitors used to treat hypertension [e.g. ACE (angiotensin-converting enzyme) inhibitors and AngII receptor antagonists] and heart disease [7] .
The G-protein heterotrimer is composed of a GDPbound G α subunit and a G βγ heterodimer. Different gene families consisting of 16α, 6β and 12γ genes encode the three subunits that can form heterotrimeric complexes in various combinations. It is the G α subunit families (G s , G q , G i etc.), however, that define the signalling context of the heterotrimer via its ability to selectively couple to a limited number of seven-transmembrane domain receptors and effectors. In the absence of extracellular ligand (inactive 'OFF' state), the G-protein heterotrimer is coupled to the intracellular surface of the receptor. Binding of receptor ligand induces the exchange of GTP for GDP on the G α subunit and the subsequent dissociation of G α from the G βγ heterodimer. This condition marks the activated ('ON') state during which time the G α and G βγ subunits are free to engage the appropriate downstream effector pathways [8, 9] . Effector signalling is terminated following G α -subunit-catalysed hydrolysis of GTP and reformation of the quiescent receptor-coupled heterotrimer. Thus G-proteins act as timed molecular switches to control the onset and lifetime of cellular responses to extracellular signals.
RGS PROTEINS PROMOTE RAPID TERMINATION OF G-PROTEIN-MEDIATED SIGNALS
G-protein signalling pathways are tightly coupled to rapid 'ON'-'OFF' kinetics of cell physiological effectors, including membrane ion channels. As the intrinsic rate of G α -mediated GTP hydrolysis is very slow, it has been suggested that GAPs (GTPase-activating proteins) are needed to achieve the rapid 'ON'-'OFF' kinetics of G-protein signalling observed in vivo [10] . RGS proteins contain an approx. 120 amino acid GAP domain [11] that can increase the rate of G α -mediated GTP hydrolysis by up to 2000 times [10] . Accordingly, RGS proteins attenuate GPCR-mediated signalling by: (i) promoting faster signal termination kinetics following removal of a GPCR agonist; and (ii) decreasing GPCR agonist sensitivity (i.e. higher agonist concentrations are needed to achieve the same degree of signalling). In addition, the RGS protein GAP domain can inhibit signalling by blocking G α binding to downstream effector molecules [12] .
Work from our laboratory and others has shown that three RGS proteins, RGS2, RGS4 and RGS5, are among the most highly expressed proteins in the heart and blood vessels. Moreover, since the genes encoding these three proteins are located within the region on chromosome 1 that is associated with BP variation, we have focused on their established roles as inhibitors of G-protein signalling in cardiovascular tissues in the present review.
RGS2

RGS2 inhibits G αq and adenylatecyclase-mediated signalling
Activation of G αq -mediated vasoconstrictor signalling pathways in VSMCs mediates the action of several vasoconstrictor agonists, including noradrenaline, AngII, vasopressin and endothelin ( Figure 2 ). RGS2 is a selective and potent inhibitor of G αq signalling [13] that is ubiquitously expressed throughout the cardiovascular system. The biological significance of RGS2 in cardiovascular physiology is evident from BP studies carried out in mice and humans. Work from our group and others have shown that Rgs2-null mice are hypertensive [14] [15] [16] , with altered G-protein signalling in a number of tissues. These mice have agonist-dependent increases in G αq signalling in both VSMCs [16, 17] and pancreatic acinar cells [18] compared with wild-type controls. Moreover, Rgs2-null mice also have altered pressor responses to infusion of AngII and α-adrenergic receptor agonists compared with wild-type controls [16] . This effect may be partly explained by increased myogenic vasoreactivity to G-protein-mediated stimuli, as was recently demonstrated in isolated renal interlobar arterioles [19] of the Rgs2-null mice. RGS2 has also been shown to be highly integrated within the NOmediated vasodilatory pathway [15, 17, 20] . Specifically, the N-terminal of RGS2 is phosphorylated by PKG (cGMP-dependent protein kinase), resulting in plasma membrane translocation and its increased function as an inhibitor of vasoconstrictor signalling [15] .
Results from knockout animal studies also suggest that abnormal autonomic nervous system function contributes to the hypertensive phenotype of these mice, since they have increased noradrenaline levels in their urine and altered baroreflex sensitivity [14] . Moreover, through the ability of its N-terminal domain to directly inhibit specific adenylate cyclase isoforms [21, 22] , RGS2 may attenuate signalling via receptors for dopamine and vasopressin in the kidney. Consistent with this suggestion, RGS2 was shown to regulate vasopressin responses in cortical collecting duct segments in vivo [23] .
Figure 2 Summary of RGS protein function in VSMCs and myocytes
Shown are the sites of action of RGS2, RGS4 and RGS5 within VSMCs, and contracting cardiac and sinoatrial node pacemaker myocytes. RGS proteins can inhibit the downstream effects of several key contractile and proliferative signals in VSMCs, some of which are shown. In cardiac myocytes, RGS proteins can inhibit both the hypertrophic response, as well as modulate signalling through the muscarinic M 2 receptor (M2R), a key modulator of parasympathetic signalling. ACh, acetylcholine; ERK, extracellular-signal-regulated kinase; IP 3 , inositol 1,4,5-trisphosphate; PLC, phospholipase C.
RGS2 and AngII
There is increasing evidence showing a reciprocal association between RGS2 activity and AngII signalling. RGS2 has been shown to modulate signalling through the AT 1 receptor (AngII type 1 receptor) in several reports mentioned above. However, Rgs2 mRNA expression can also be increased by AngII signalling in several cell lines [24] [25] [26] [27] [28] [29] , suggesting that RGS2 is an important part of a negative-feedback loop for this pathway. Indeed, the AngII-stimulated expression of Rgs2 has been shown to be able to inhibit both AngII signalling [27] and aldosterone production [28] . Although the precise mechanism for the up-regulation of Rgs2 is not fully understood, recent findings have implicated a role for PLA 2 (phospholipase A 2 ) in this process [29] . Together, these results suggest a reciprocal relationship between RGS2 and AngII, which is supported by in vivo studies showing that the Rgs2-null animals are more sensitive to AngII-induced hypertension than wild-type controls [19] .
RGS2 attenuates GPCR signalling in the heart
In addition to its established function in VSMCs, a biological role for RGS2 in the heart has also been proposed ( Figure 2 ). Several groups have suggested a potential role for RGS2 in attenuating hypertrophic signalling in the heart. Aortic banding studies have shown that RGS2 expression levels are increased during the hypertrophic response, a pathway known to involve G αq function [30] . Moreover, RGS2 overexpression can ameliorate the hypertrophic response of cultured cardiac myocytes to α 1 -adrenergic stimulation, whereas RGS2 knockdown exacerbated this response [31, 32] . In light of these interesting observations, the role of endogenous RGS2 in cardiac myoctyes will need to be characterized in the intact animal.
Clinical hypertension: implications for its association with RGS2 deficiency
The current body of evidence points to an important role for RGS2 in the regulation of BP homoeostasis. The lessons learned from studying BP in Rgs2-null mice may also be relevant to understanding BP variation in human populations. For example, several recent studies have identified human genetic polymorphisms within the RGS2 locus that are associated with hypertension in different ethnic populations [33] [34] [35] [36] . The RGS2 gene consists of five exons that show minimal genetic variation between subjects. No coding polymorphisms were identified in Caucasian subjects; however, one such SNP (single nucleotide polymorphism) was found in Black Americans [36] , and nine in Japanese subjects (of which five are non-synonymous) [37] . In the case of the Japanese population, hypomorphic RGS2 allele function may, in part, explain the development of hypertension in subjects carrying missense mutations at Q2L, Q2R and R44H. For example, Q2L and Q2R variant proteins were shown to be less stable compared with normal RGS2 and, as a result, these subjects are thought to express lower steady-state levels of RGS2 [33] . By contrast, our work has shown that the R44H variant of RGS2, although not compromising stability, did disrupt the amphipathic α-helix that is crucial for proper plasma-membrane targeting and function [38] . Notably, another mutation at the Arg 44 position, R44G, has also been shown to be associated with hypertension and higher than normal BMI (body mass index) [39] , perhaps suggesting a link between RGS2 and obesity and the metabolic syndrome. In addition to those changes identified in the coding regions, the promoter region, introns and untranslated regions of RGS2 also contain several SNPs and I/D (insertion/deletion) polymorphisms, of which one has been shown to result in enhanced calcium mobilization in fibroblasts in their response to AngII [40] , and one that has been linked to an increase in risk of the metabolic syndrome in white Caucasian Europeans [34] . Moreover, their allelic frequency differs markedly between ethnic groups, and some are exclusively found in one ethnicity [33, 34, 36] . Taken together, these studies of both non-synonymous mutations and extra-exonic polymorphisms suggest the possibility that RGS2 variation contributes to some of the BP variation observed between different ethnic groups.
Ironically, too much RGS2 may also provide a pathophysiological stimulus within some cardiovascular tissues. It has been reported that the RGS2 protein is overexpressed in patients with B/S (Bartter's syndrome) and Gitelman's syndromes (G/S), and that this abnormally high expression inhibits AngII-mediated intracellular calcium release [41] and altered vascular remodelling in these patients. Indeed, fibroblasts taken from patients with B/S and G/S have enhanced RGS2 expression and greatly reduced signalling through the AT 1 receptor [24] , the effects of which can be normalized by the knockdown of RGS2 expression [42] . Taken together these findings suggest that the precise control of RGS2 protein level and function appears to be extremely important for normal regulation of vascular function and BP.
RGS5
RGS5: a signalling molecule in VSMCs and pericytes
Of the more than 35 mammalian RGS proteins identified thus far, RGS5 is the only one to show robust and highly restricted expression in mural cells of the arteries and microcirculation. Microarray analysis has shown that Rgs5 mRNA was 46-fold more highly expressed in arteries compared with veins [43] . Within arterial VSMCs, RGS5 has been shown to act as a GTPase-activating factor for a number of G αi -and G αq -mediated pathways, including those of AngII, endothelin-1 and S1P [33, [44] [45] [46] . Furthermore, ribozyme-mediated knockdown of Rgs5 mRNA in A10 cells (a VSMC cell line) in culture results in increased AngII-mediated MAPK activation [47] , suggesting that endogenous RGS5 levels are sufficient to inhibit this signalling pathway in VSMCs (Figure 2 ).
Rgs5 expression is dynamically regulated during development and disease
Arterial VSMCs and pericytes of the developing murine vasculature have a high expression of Rgs5 [44, 48] . Moreover, in adult mice, Rgs5 expression has been shown to be increased in the mural cell compartment of arteries during neovascularization associated with skin wound-healing [49] and tumour angiogenesis [50, 51] . Thus increased expression of Rgs5 appears to be associated with VSMC specification and investment during vasculogenesis.
By contrast, analysis of advanced atherosclerotic lesions from primates showed that Rgs5 mRNA levels were markedly reduced in smooth muscle cells from intimal lesions and stable fibrous plaques [52] . Moreover, treatment of atherogenic animals with statin class drugs resulted in a marked up-regulation of Rgs5 mRNA in the aorta [53] . Thus Rgs5 expression levels appear to correlate inversely with the proliferative status of VSMCs in atherogenic models. These findings support the notion that the loss of RGS5 function may be necessary to support G-protein-mediated migration and proliferation of mural cells. Rgs5 mRNA expression is also down-regulated in stroke-prone CNS (central nervous system) microvessels and choroidus plexus, a condition that is associated with susceptibility to cerebral haemorrhage [54] . These results suggest that RGS5 may normally provide protection to CNS vessels, particularly under conditions of increased systemic BP.
Rgs5-null mice are hypotensive
Although these initial findings pointed to the possibility that Rgs5-null mice would be hypertensive, two independent groups have reported that these knockout animals are, in fact, hypotensive relative to wild-type controls [55, 56] . Kehrl and co-workers [55] propose that the lower than normal BP may be related to an increased susceptibility to NO signalling at the level of VASP (vasodilator-stimulated phosphoprotein) and ERK1/2 (extracellular-signal-regulated kinase 1/2) phosphorylation. It may be important that the hypotensive phenotype was more obvious in waking (tail-cuff plethysmography) compared with anaesthetized animals. It will thus be interesting to determine the extent to which altered sympathetic activity, peripheral resistance, baroreceptor function and cardiac output contribute to the interesting BP phenotype reported.
RGS5 function inhibits vascular stabilization in pancreatic tumour models
Despite the robust expression of Rgs5 at critical stages of VSMC and pericyte specification during neovascularization, no gross vascular development defects were reported in three different knockout mouse strains [55] [56] [57] . A possible exception is the reported modest dilation of the aorta in Rgs5-null animals; however, this is thought to be a consequence of the hypotensive condition of these animals during development rather than from the loss of RGS5 in aortic VSMCs [55] . Importantly, however, Rgs5-null animals have increased stabilization of the tumour vasculature in a genetic model of pancreatic carcinoma, a condition that made these tumours more sensitive to specific immunotherapy strategies [57] . This phenotype may be dependent on the pathophysiological model studied, however, since Nisancioglu et al. [56] found no marked difference in the vascular stabilization phenotype of subcutaneous T241 cell tumours or oxygen-induced retinopathies in Rgs5-null compared with wild-type mice. Nonetheless, identifying ways to reduce Rgs5 expression or function in tumour vessels may be an effective strategy for improving the therapeutic window in certain tumours.
RGS4
RGS4: an important regulator of cardiac myocyte function
RGS4 shares a high degree of sequence similarity with RGS5 and is likewise capable of inhibiting both G αq -and G αi -coupled signalling. Although originally characterized as the brain-selective RGS isoform, RGS4 has been strongly implicated in the regulation of cardiac cell signalling and accordingly is expressed in both atrial and ventricular myocytes [58] [59] [60] . It is of clinical interest that Rgs4 is reported to be up-regulated during conditions of pathophysiological stress. Specifically, in hypertrophied ventricles from pulmonary artery-or aortic-banded mice, Rgs4 mRNA expression levels are increased relative to normal tissue [30, 60, 61] . In left ventricular myocardium from failing compared with non-failing donor human hearts, RGS4 mRNA and protein levels are higher by 2-3-fold [59, 62] . Careful investigation of the species-and ventricle-specific nature of these changes may be required, however, as hypertrophied hearts from neither guinea-pig nor rat models had increased levels of Rgs4 expression [60, 63] .
RGS4 inhibits G αq -mediated hypertrophic signalling in cardiomyocytes
Direct evidence that RGS4 can inhibit hypertrophic signalling came from an important series of studies by Muslin and co-workers [64] . First, they showed that RGS4 overexpression in neonatal cardiac myocytes inhibits phenylephrine-and endothelin-induced myofilament organization and cell growth [64] . Consistent with this original report, transgenic expression of RGS4 in mouse cardiomyocytes prevented the hypertrophic response to either aortic banding [65] or G αq overexpression [66] . Taken together, these results indicate that RGS4 can regulate G-protein-mediated hypertrophic signalling in mouse ventricular myocytes, particularly under conditions where it is highly expressed (Figure 2 ). More recently, RGS4 overexpression has also been reported to mediate the cGMP/PKG-dependent inhibition of hypertrophic signalling in cardiomyocytes in vivo [61] . It remains to be determined, however, whether the endogenous levels of RGS4 expression are necessary for the proper regulation of antihypertrophic signalling pathways.
RGS4 may also regulate chronotropic responses in atrial myocytes
Several papers from Doupnik and co-workers [67] [68] [69] [70] [71] have demonstrated a functional link between RGS4 and the regulation of muscarinic M 2 receptormediated activation of GIRK (G-protein-coupled inward rectifying potassium) channels in atrial myocytes (Figure 2 ). GIRK channel activation via G αi class proteins coupled to muscarinic M 2 receptors is a key pathway mediating the hyperpolarizing effects of parasympathetic signalling on atrial myocytes [72] [73] [74] . Rgs4 is expressed in isolated atrial myocytes [58, 60] , and has been shown to selectively associate with the M 2 receptor and GIRK channels in pulldown experiments [69] . Importantly RGS4 was recently shown to be a powerful modulator of GIRK channel activation in isolated atrial myocytes [75] . Thus, through its ability to co-ordinate G αi -mediated regulation of GIRK channel activation, RGS4 was predicted to be a potentially important inhibitor of the negative chronotropic actions of parasympathetic signalling and activity. Expression of RGS-resistant G αi or G αo from their endogenous promoters in mice greatly reduced pacemaker cell automaticity and responsiveness to parasympathetic stimulation [76, 77] ; however, the specific RGS protein(s) controlling parasympathetic signalling were not identified. Recent work from our laboratory has shown that Rgs4 is expressed at much higher levels in sinoatrial node myocytes compared with the working myocardium [78] . Consistent with a role for RGS4 in regulating pacemaker function, RGS4-deficient mice had increased response to M 2 muscarinic receptor activation at the level of the intact animal, isolated heart and myocytes from the sinoatrial node. Moreover, sinoatrial node cells lacking RGS4 also had decreased levels of GIRK channel desensitization and altered modulation of I KACh (acetylcholine-activated K + current) kinetics following parasympathetic stimulation [78] .
SUMMARY AND PERSPECTIVES
The RGS protein superfamily was discovered just over a decade ago. Indeed, the potential biological roles of many of these proteins identified still remain to be identified. In the present review, we have focused on RGS2, RGS4 and RGS5, three proteins that are known inhibitors of important GPCR signalling pathways in the cardiovascular system and are highly expressed in tissues that are critical for the regulation of BP. Figures 1 and 2 respectively, summarize the sites of RGS2, RGS4 and RGS5 expression and their functional interactions with GPCR signalling pathways that mediate BP regulation and cardiovascular function. Notably, despite their apparent functional similarities, these proteins show markedly different expression patterns and affinities for the regulation of Gprotein signalling. Thus, even in the same tissue, different cells are likely to have unique RGS expression profiles based on their specific physiological role within that tissue. A notable example of this point is the highly selective expression of RGS4 in the pacemaker cells of the sinoatrial node. Thus reporter gene strategies, combined with tissue-and cell-specific knockout mice, will be an important step forward in identifying new roles for RGS proteins that may not be obvious from whole-animal knockouts due to compensatory mechanisms. Thus, although we have focused in the present review on RGS2, RGS4 and RGS5, the development of new genetic tools, such as those just mentioned, could result in the discovery of a growing number of RGS family members that control cardiovascular development and BP regulation. 
